Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)/ Multifocal Motor Neuropathy (MMN)
Conditions
Interventions
None listed
Sponsors
Takeda Pharmaceutical Company Limited.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Physicians who are members of medical societies for: -General internal medicine -Orthopedics -Neurology
Exclusion criteria
Exclusion criteria: The following physicians are excluded: - Have less than 2 years of clinical practice excluding their training periods - Who are not actively practicing physicians or work in facilities other than clinics, university hospitals, general hospitals, and national and public hospitals - Who are currently treating no outpatients and inpatients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -To determine the levels of awareness of CIDP/MMN among non-specialists (general internist and orthopedist) -To determine the level of awareness of CIDP/MMN among specialists (neurologists) | — |
Secondary
| Measure | Time frame |
|---|---|
| -To identify factors that lead to misdiagnosis of CIDP/MMN among specialists -To determine key factors used to support diagnosis and treatment decisions in CIDP/MMN | — |
Countries
Japan
Contacts
Public ContactAiko Misaki
Takeda Pharmaceutical Company Limited. Japan Medical Office
Outcome results
None listed